Evaluating Parp1 domains as gossypol targets


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Poly ADP-ribose Polymerase 1 (PARP1) is an important enzyme that is involved in DNA repair, replication, and transcription. Prospective anticancer drug gossypol inhibits human PARP1, but the mechanism of inhibition remains unknown. It has been shown previously that gossypol interacts with purified BRCA1 C-terminus (BRCT) domain in vitro. However, it remained unclear whether gossypol inhibits PARP1 through the BRCT domain in the context of full-length protein. Here, we report that the BRCT domain within the full-length PARP1 protein is not required for the inhibition of catalytic activity of PARP1 by gossypol. Our results, obtained using a series of PARP1 mutations and H4-dependent pathway of PARP1 activation, also show that none of the zinc fingers or other DNA binding domains of PARP1 are involved in the inhibition of the PARP1 catalytic activity by gossypol. Thus, the likely candidate target(s) for gossypol action are the other domains of PARP1, or the interdomain linkers.

作者简介

S. Gross

Cancer Epigenetics Team

Email: mal_nat@mail.ru
美国, Philadelphia, PA, 19111

E. Kotova

Cancer Epigenetics Team

Email: mal_nat@mail.ru
美国, Philadelphia, PA, 19111

N. Maluchenko

Department of Biology

编辑信件的主要联系方式.
Email: mal_nat@mail.ru
俄罗斯联邦, Moscow, 119234

J. Pascal

Department of Biochemistry and Molecular Medicine

Email: mal_nat@mail.ru
加拿大, Montréal, QC, H3C 3J7

V. Studitsky

Cancer Epigenetics Team; Department of Biology

Email: mal_nat@mail.ru
美国, Philadelphia, PA, 19111; Moscow, 119234

补充文件

附件文件
动作
1. JATS XML

版权所有 © Allerton Press, Inc., 2016